PharmaEssentia Honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the Introduction of BESREMi® (ropeginterferon alfa-2b-njft) for Polycythemia Vera
PharmaEssentia was selected as one of the 2022 Industry Award Honorees, underscoring the significance of…